Epigenetic targeting of Waldenström macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition.
Epigenomics
; 13(2): 129-144, 2021 01.
Article
en En
| MEDLINE
| ID: mdl-33356554
ABSTRACT
Aim:
Waldenström macroglobulinemia (WM) is a low-grade B-cell lymphoma characterized by overproduction of monoclonal IgM. To date, there are no therapies that provide a cure for WM patients, and therefore, it is important to explore new therapies. Little is known about the efficiency of epigenetic targeting in WM. Materials &methods:
WM cells were treated with BET inhibitors (JQ1 and I-BET-762) and venetoclax, panobinostat or ibrutinib.Results:
BET inhibition reduces growth of WM cells, with little effect on survival. This finding was enhanced by combination therapy, with panobinostat (LBH589) showing the highest synergy.Conclusion:
Our studies identify BET inhibitors as effective therapy for WM, and these inhibitors can be enhanced in combination with BCL2 or histone deacetylase inhibition.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Macroglobulinemia de Waldenström
/
Receptores de Superficie Celular
/
Proteínas Proto-Oncogénicas c-bcl-2
/
Epigénesis Genética
/
Inhibidores de Histona Desacetilasas
/
Proteínas del Tejido Nervioso
/
Antineoplásicos
Tipo de estudio:
Prognostic_studies
Límite:
Humans
Idioma:
En
Revista:
Epigenomics
Año:
2021
Tipo del documento:
Article
País de afiliación:
Estados Unidos